atrasentan has been researched along with Anoxemia in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cho, H; Koutcher, JA; Li, XF; Ling, CC; Lupu, ME; Russell, J; Yang, KM | 1 |
Borel Rinkes, IH; Duyverman, AM; Kranenburg, O; Nijkamp, MW; Soeters, ME; van der Bilt, JD; van Diest, PJ; Witteveen, PO | 1 |
Chen, SJ; Chen, YF; DiCarlo, VS; Durand, J; Meng, QC; Oparil, S; Opgenorth, TJ; Wessale, JL | 1 |
Chen, YF; Oparil, S | 1 |
1 review(s) available for atrasentan and Anoxemia
Article | Year |
---|---|
Endothelial dysfunction in the pulmonary vascular bed.
Topics: Animals; Antihypertensive Agents; Atrasentan; Bosentan; Controlled Clinical Trials as Topic; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstructive; Nitric Oxide; Oligopeptides; Peptides, Cyclic; Piperidines; Pulmonary Circulation; Pyrrolidines; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Time Factors; Vasoconstriction; Vasodilation | 2000 |
3 other study(ies) available for atrasentan and Anoxemia
Article | Year |
---|---|
Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.
Topics: Adenocarcinoma; Animals; Atrasentan; Colonic Neoplasms; Combined Modality Therapy; Etanidazole; Gadolinium DTPA; HT29 Cells; Humans; Hydrocarbons, Fluorinated; Hypoxia; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Nitroimidazoles; Perfusion; Pyrrolidines; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases.
Topics: Animals; Arginine; Atrasentan; Benzoquinones; Cell Line, Tumor; Colorectal Neoplasms; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Lactams, Macrocyclic; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Microcirculation; Necrosis; Neoplasm Transplantation; Pyrrolidines; Reperfusion Injury; Time Factors; Tumor Burden | 2007 |
The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.
Topics: Animals; Atrasentan; Blood Pressure; Cardiomegaly; Endothelin Receptor Antagonists; Endothelin-1; Heart Rate; Hypertension, Pulmonary; Hypoxia; Male; Pulmonary Artery; Pyrrolidines; Rats; Receptor, Endothelin A | 1997 |